MXPA03000787A - Receptores del factor de diferenciacion de crecimiento, agonistas y antagonistas de los mismos, y metodos de usarlos. - Google Patents
Receptores del factor de diferenciacion de crecimiento, agonistas y antagonistas de los mismos, y metodos de usarlos.Info
- Publication number
- MXPA03000787A MXPA03000787A MXPA03000787A MXPA03000787A MXPA03000787A MX PA03000787 A MXPA03000787 A MX PA03000787A MX PA03000787 A MXPA03000787 A MX PA03000787A MX PA03000787 A MXPA03000787 A MX PA03000787A MX PA03000787 A MXPA03000787 A MX PA03000787A
- Authority
- MX
- Mexico
- Prior art keywords
- cell
- provides
- myostatin
- modulating
- gdf
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 230000004069 differentiation Effects 0.000 title abstract 2
- 239000000556 agonist Substances 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 102000004472 Myostatin Human genes 0.000 abstract 6
- 108010056852 Myostatin Proteins 0.000 abstract 6
- 210000004027 cell Anatomy 0.000 abstract 4
- 210000000577 adipose tissue Anatomy 0.000 abstract 3
- 230000019491 signal transduction Effects 0.000 abstract 3
- 210000003205 muscle Anatomy 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002503 metabolic effect Effects 0.000 abstract 1
- 210000000663 muscle cell Anatomy 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0362—Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
- C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/495—Transforming growth factor [TGF]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Environmental Sciences (AREA)
- Hematology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Animal Husbandry (AREA)
- Obesity (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Plant Pathology (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
Abstract
La presente invencion provee un receptor del factor de diferenciacion de crecimiento (GDF) sustancialmente purificado, incluyendo un receptor de GDF-8 (miostatina), asi como porciones peptidas funcionales del mismo. En adicion, la invencion provee una representacion virtual de un receptor de GDF o una porcion peptida funcional del mismo. La presente invencion tambien provee un metodo de modular un efecto de miostatina sobre una celula poniendo en contacto la celula con un agente que afecta la transduccion de senal de miostatina en la celula. En adicion, la invencion provee un metodo de mejorar la severidad de una condicion patologica, que se caracteriza, al menos en parte, por una cantidad anormal de desarrollo de actividad metabolica de tejido de musculo o adiposo en un sujeto, modulando la transduccion de senal de miostatina en una celula de musculo o celula de tejido adiposo en el sujeto. La invencion tambien provee un metodo de modular el crecimiento de tejido de musculo o tejido adiposo en un organismo eucariotico administrando un agente que afecta la transduccion de senal de miostatina al organismo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/626,896 US6656475B1 (en) | 1997-08-01 | 2000-07-27 | Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
PCT/US2001/023615 WO2002010214A2 (en) | 2000-07-27 | 2001-07-26 | Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA03000787A true MXPA03000787A (es) | 2004-05-21 |
Family
ID=24512319
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA03000787A MXPA03000787A (es) | 2000-07-27 | 2001-07-26 | Receptores del factor de diferenciacion de crecimiento, agonistas y antagonistas de los mismos, y metodos de usarlos. |
Country Status (19)
Country | Link |
---|---|
US (1) | US6656475B1 (es) |
EP (2) | EP2322199B1 (es) |
JP (2) | JP5153985B2 (es) |
CN (2) | CN101402955A (es) |
AR (1) | AR033384A1 (es) |
AT (1) | ATE503487T1 (es) |
AU (2) | AU2001282999B2 (es) |
BR (1) | BR0112788A (es) |
CA (1) | CA2417568C (es) |
DE (1) | DE60144334D1 (es) |
DK (1) | DK1317485T3 (es) |
ES (2) | ES2364126T3 (es) |
IL (2) | IL153975A0 (es) |
MX (1) | MXPA03000787A (es) |
NZ (2) | NZ523617A (es) |
PL (1) | PL365792A1 (es) |
PT (1) | PT1317485E (es) |
WO (1) | WO2002010214A2 (es) |
ZA (1) | ZA200300480B (es) |
Families Citing this family (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7393682B1 (en) * | 1993-03-19 | 2008-07-01 | The Johns Hopkins University School Of Medicine | Polynucleotides encoding promyostatin polypeptides |
US7566768B1 (en) | 1995-10-26 | 2009-07-28 | The Johns Hopkins University School Of Medicine | Promyostatin peptides and methods of using same |
CA2157577C (en) * | 1993-03-19 | 2009-11-17 | Se-Jin Lee | Growth differentiation factor-8 |
US6891082B2 (en) * | 1997-08-01 | 2005-05-10 | The Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a truncated activintype II receptor |
TW200526779A (en) * | 2001-02-08 | 2005-08-16 | Wyeth Corp | Modified and stabilized GDF propeptides and uses thereof |
US7320789B2 (en) * | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
PL374966A1 (en) * | 2002-02-21 | 2005-11-14 | Wyeth | Follistatin domain containing proteins |
CA2476887A1 (en) * | 2002-02-21 | 2003-09-04 | Wyeth | Gasp1:a follistatin domain containing protein |
US7193069B2 (en) | 2002-03-22 | 2007-03-20 | Research Association For Biotechnology | Full-length cDNA |
JP2006507356A (ja) * | 2002-09-16 | 2006-03-02 | ワイエス | ミオスタチンのメタロプロテアーゼ活性化およびミオスタチン活性の調節方法 |
AR047392A1 (es) | 2002-10-22 | 2006-01-18 | Wyeth Corp | Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines |
US20040223966A1 (en) * | 2002-10-25 | 2004-11-11 | Wolfman Neil M. | ActRIIB fusion polypeptides and uses therefor |
US7511012B2 (en) | 2002-12-20 | 2009-03-31 | Amgen Inc. | Myostatin binding agents |
UA85055C2 (ru) | 2003-06-02 | 2008-12-25 | Уайт | Применение ингибиторов миостатика (gdf8) в сочетании с кортикостероидами для лечения нервно-мышечных заболеваний |
KR20060120229A (ko) * | 2003-12-31 | 2006-11-24 | 쉐링-프라우 리미티드 | 중화 에피토프계 성장 증진 백신 |
JP4688483B2 (ja) | 2004-04-15 | 2011-05-25 | 株式会社テクノネットワーク四国 | フォリスタチン変異体ポリペプチド |
US9045553B2 (en) | 2004-05-27 | 2015-06-02 | Acceleron Pharma, Inc. | Cerberus/Coco derivatives and uses thereof |
US20100183695A1 (en) | 2004-05-27 | 2010-07-22 | John Knopf | Cerberus/coco derivatives and uses thereof |
EP2314617B1 (en) | 2004-07-23 | 2015-06-24 | Acceleron Pharma Inc. | ActRII receptor polypeptides |
WO2006025988A1 (en) * | 2004-07-29 | 2006-03-09 | Schering-Plough Ltd. | Use of alk 5 inhibitors to modulate or inhibit myostatin activity leading to increased lean tissue accretion in animals |
US20060034831A1 (en) * | 2004-08-12 | 2006-02-16 | Wyeth | Combination therapy for diabetes, obesity and cardiovascular diseases using GDF-8 inhibitors |
CA2582940A1 (en) | 2004-09-30 | 2006-04-06 | Orico Limited | Myostatin isoform |
JP2008000003A (ja) * | 2004-10-01 | 2008-01-10 | Oncorex Inc | Pim−1活性/蛋白阻害医薬品 |
CA2594276A1 (en) * | 2004-12-30 | 2006-07-13 | Schering-Plough Ltd. | Neutralizing epitope-based growth enhancing vaccine |
CN101137906A (zh) * | 2005-03-23 | 2008-03-05 | 惠氏公司 | 对gdf-8调节剂的免疫应答的检测 |
GB2441581B (en) * | 2005-06-24 | 2011-01-19 | Roderic M K Dale | Compositions and methods for the treatment of muscle wasting |
WO2008005002A1 (en) * | 2006-06-30 | 2008-01-10 | Oligos Ets. Inc. | Compositions and methods for the treatment of muscle wasting |
CN100393320C (zh) * | 2005-06-24 | 2008-06-11 | 奥林格斯技术有限公司 | 治疗肌肉萎缩的寡核苷酸药物 |
JP5052517B2 (ja) * | 2005-10-06 | 2012-10-17 | イーライ リリー アンド カンパニー | 抗ミオスタチン抗体 |
UA92504C2 (en) | 2005-10-12 | 2010-11-10 | Эли Лилли Энд Компани | Anti-myostatin monoclonal antibody |
US8067562B2 (en) | 2005-11-01 | 2011-11-29 | Amgen Inc. | Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1 |
US8128933B2 (en) * | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
CN104844713B (zh) | 2005-11-23 | 2021-05-14 | 阿塞勒隆制药公司 | Activin-ActRIIa拮抗剂及其促进骨骼生长的应用 |
JP2009518422A (ja) * | 2005-12-06 | 2009-05-07 | アムジェン インコーポレイテッド | ミオスタチン・アンタゴニストの使用 |
JP2007306885A (ja) * | 2006-05-22 | 2007-11-29 | Mitsubishi Chemicals Corp | 新規非ヒト動物 |
US8097596B2 (en) * | 2006-06-30 | 2012-01-17 | Lakewood-Amedex, Inc. | Compositions and methods for the treatment of muscle wasting |
WO2008005019A1 (en) * | 2006-07-07 | 2008-01-10 | Dale Roderic M K | Compositions and methods for the treatment of muscle wasting |
AU2007279456A1 (en) | 2006-08-03 | 2008-02-07 | Myostin Therapeutics Pty Ltd | Myostatin antagonists |
AU2007292555B2 (en) * | 2006-09-05 | 2012-05-31 | Eli Lilly And Company | Anti-myostatin antibodies |
AU2007332819A1 (en) | 2006-12-08 | 2008-06-19 | Acceleron Pharma Inc. | Uses of cerberus, coco and derivatives thereof |
US8895016B2 (en) * | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
US20100028332A1 (en) * | 2006-12-18 | 2010-02-04 | Acceleron Pharma Inc. | Antagonists of actriib and uses for increasing red blood cell levels |
BRPI0720476B1 (pt) * | 2006-12-18 | 2022-05-31 | Acceleron Pharma Inc | Uso de um polipeptídeo de actrii para tratar anemia em um paciente humano |
BRPI0806861A2 (pt) * | 2007-02-01 | 2014-08-05 | Acceleron Pharma Inc | Antagonistas de ativina-actriia e usos para tratar ou prevenir câncer de mama |
TW201940502A (zh) | 2007-02-02 | 2019-10-16 | 美商艾瑟勒朗法瑪公司 | 衍生自ActRIIB的變體與其用途 |
TWI525102B (zh) | 2007-02-09 | 2016-03-11 | 艾瑟勒朗法瑪公司 | 包含ActRIIa-Fc融合蛋白的醫藥組合物;ActRIIa-Fc融合蛋白於治療或預防與癌症相關的骨質流失之用途;ActRIIa-Fc融合蛋白於治療或預防多發性骨髓瘤之用途 |
US8501678B2 (en) | 2007-03-06 | 2013-08-06 | Atara Biotherapeutics, Inc. | Variant activin receptor polypeptides and uses thereof |
TW201718635A (zh) | 2007-03-06 | 2017-06-01 | 安美基公司 | 變異之活動素受體多肽及其用途 |
CN103877564A (zh) | 2007-09-18 | 2014-06-25 | 阿塞勒隆制药公司 | 活化素-actriia拮抗剂和减少或抑制fsh分泌的用途 |
PE20091163A1 (es) * | 2007-11-01 | 2009-08-09 | Wyeth Corp | Anticuerpos para gdf8 |
US20100015144A1 (en) | 2008-06-26 | 2010-01-21 | Acceleron Pharma Inc. | Methods for dosing an activin-actriia antagonist and monitoring of treated patients |
US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
TWI784538B (zh) | 2008-08-14 | 2022-11-21 | 美商艾瑟勒朗法瑪公司 | 使用gdf阱以增加紅血球水平 |
EA201791940A3 (ru) | 2008-11-26 | 2018-04-30 | Амген Инк. | Варианты полипептидов рецептора iib активина и их использование |
WO2010083034A1 (en) | 2009-01-13 | 2010-07-22 | Acceleron Pharma Inc. | Methods for increasing adiponectin |
NO2424895T3 (es) | 2009-04-27 | 2018-02-03 | ||
CN102482339B (zh) * | 2009-06-08 | 2015-06-17 | 阿塞勒隆制药公司 | 用于增加产热脂肪细胞的方法 |
KR20180026795A (ko) | 2009-06-12 | 2018-03-13 | 악셀레론 파마 인코포레이티드 | 절두된 ActRIIB-FC 융합 단백질 |
JP5836961B2 (ja) * | 2009-11-03 | 2015-12-24 | アクセルロン ファーマ, インコーポレイテッド | 脂肪肝疾患を処置するための方法 |
ES2658292T3 (es) | 2009-11-17 | 2018-03-09 | Acceleron Pharma, Inc. | Proteínas ActRIIB y variantes y usos de las mismas con respecto a la inducción de la utrofina para el tratamiento de la distrofia muscular |
CN103298832A (zh) | 2010-11-08 | 2013-09-11 | 阿塞勒隆制药公司 | Actriia结合剂及其用途 |
EP2793925B1 (en) | 2011-12-19 | 2019-03-20 | Amgen Inc. | Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof |
NZ630914A (en) | 2012-04-18 | 2017-01-27 | Nogra Pharma Ltd | Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation |
EP3964224A1 (en) | 2012-11-02 | 2022-03-09 | Celgene Corporation | Activin-actrii antagonists and uses for use in treating renal disease |
CA3023553A1 (en) * | 2012-11-06 | 2014-05-15 | Scholar Rock, Inc. | Compositions and methods for modulating cell signaling |
JP2016508504A (ja) | 2013-02-01 | 2016-03-22 | サンタ マリア バイオセラピューティクス インコーポレイテッド | 対象に対する抗アクチビン−a化合物の投与 |
JP2016518357A (ja) | 2013-04-08 | 2016-06-23 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 骨格筋幹細胞を若返らせる方法および組成物 |
LT2981822T (lt) | 2013-05-06 | 2020-12-28 | Scholar Rock, Inc. | Kompozicijos ir būdai, skirti augimo faktoriaus moduliacijai |
EP3881859B1 (en) | 2013-06-11 | 2024-03-06 | President and Fellows of Harvard College | Compositions for increasing neurogenesis and angiogenesis |
WO2015070076A2 (en) * | 2013-11-08 | 2015-05-14 | President And Fellows Of Harvard College | Methods and compositions for rejuvenating neuromuscular junctions |
US10010498B2 (en) | 2014-06-04 | 2018-07-03 | Acceleron Pharma Inc. | Methods for treatment of amyotrophic lateral sclerosis with follistatin fusion proteins |
WO2015187977A1 (en) | 2014-06-04 | 2015-12-10 | Acceleron Pharma, Inc. | Methods and compositions for treatment of disorders with follistatin polypeptides |
BR122023023170A2 (pt) | 2014-06-13 | 2024-02-20 | Acceleron Pharma Inc. | Uso de um antagonista de actrii no tratamento ou prevenção de úlcera cutânea associada com beta-talassemia |
MA41052A (fr) | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
CA3005158A1 (en) | 2014-11-06 | 2016-05-12 | Scholar Rock, Inc. | Anti-pro/latent-myostatin antibodies and uses thereof |
ES2946160T3 (es) | 2014-12-03 | 2023-07-13 | Celgene Corp | Antagonistas de activina-ActRII y usos para tratar síndrome mielodisplásico |
WO2016154601A1 (en) | 2015-03-26 | 2016-09-29 | Acceleron Pharma Inc. | Follistatin-related fusion proteins and uses thereof |
ES2856001T3 (es) | 2015-04-22 | 2021-09-27 | Biogen Ma Inc | Nuevas proteínas híbridas de bloqueo del ligando actriib para tratar enfermedades de atrofia muscular |
CN113896790A (zh) | 2015-09-15 | 2022-01-07 | 供石公司 | 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其用途 |
WO2017120450A1 (en) | 2016-01-06 | 2017-07-13 | President And Fellows Of Harvard College | Treatment with gdf11 prevents weight gain, improves glucose tolerance and reduces hepatosteatosis |
AU2017206069A1 (en) | 2016-01-08 | 2018-07-19 | Scholar Rock, Inc. | Anti-pro/latent myostatin antibodies and methods of use thereof |
EP3426680A4 (en) | 2016-03-10 | 2020-03-11 | Acceleron Pharma Inc. | TYPE 2 ACTIVIN RECEPTOR BINDING PROTEINS AND USES THEREOF |
CN105699661A (zh) * | 2016-03-14 | 2016-06-22 | 陈倩 | Smad6在肝癌诊断治疗中的应用 |
AU2017283546C1 (en) | 2016-06-13 | 2020-11-19 | Scholar Rock, Inc. | Use of myostatin inhibitors and combination therapies |
EP4218817A3 (en) | 2017-01-06 | 2023-09-06 | Scholar Rock, Inc. | Methods for treating metabolic diseases by inhibiting myostatin activation |
CN107267637B (zh) * | 2017-07-25 | 2021-08-24 | 华南农业大学 | 一种鸡肌间脂肪宽度相关的分子标记及其应用 |
CN109540818A (zh) * | 2018-12-21 | 2019-03-29 | 云南农业大学 | 一种基于钙、磷血液生化标记选育武定鸡的方法 |
CN109754858B (zh) * | 2019-01-11 | 2021-09-21 | 余鹏 | 甲氨蝶呤给药方案确定装置、存储介质及设备 |
CA3153062A1 (en) | 2019-09-03 | 2021-03-11 | Novartis Ag | Treatment of liver disease or disorder comprising actrii receptor antagonists |
CA3184852A1 (en) | 2020-07-10 | 2022-01-13 | Lida Katsimpardi | Use of gdf11 to diagnose and treat anxiety and depression |
CN113223607B (zh) * | 2021-05-28 | 2023-10-20 | 北京化工大学 | 采用smiles算法随机批量生成肝素类似物结构坐标的方法 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5314695A (en) | 1990-11-13 | 1994-05-24 | Corvas International, Inc. | Tissue factor based prothrombin time reagent |
US5885794A (en) | 1991-05-10 | 1999-03-23 | The Salk Institute For Biological Studies | Recombinant production of vertebrate activin receptor polypeptides and identification of receptor DNAs in the activin/TGF-β superfamily |
US5994618A (en) | 1997-02-05 | 1999-11-30 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 transgenic mice |
CA2157577C (en) | 1993-03-19 | 2009-11-17 | Se-Jin Lee | Growth differentiation factor-8 |
US6465239B1 (en) * | 1993-03-19 | 2002-10-15 | The John Hopkins University School Of Medicine | Growth differentiation factor-8 nucleic acid and polypeptides from aquatic species and non-human transgenic aquatic species |
US5734039A (en) | 1994-09-15 | 1998-03-31 | Thomas Jefferson University | Antisense oligonucleotides targeting cooperating oncogenes |
WO1998033887A1 (en) | 1997-02-05 | 1998-08-06 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-8 |
EP0981745A1 (en) * | 1997-05-16 | 2000-03-01 | The Procter & Gamble Company | The use of a bone morphogenetic protein (bmp) receptor complex for screening |
AU8666398A (en) | 1997-08-01 | 1999-02-22 | Johns Hopkins University School Of Medicine, The | Methods to identify growth differentiation factor (gdf) receptors |
US6891082B2 (en) * | 1997-08-01 | 2005-05-10 | The Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a truncated activintype II receptor |
CA2319703C (en) * | 1998-02-05 | 2005-09-20 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-8 |
US6004937A (en) | 1998-03-09 | 1999-12-21 | Genetics Institute, Inc. | Use of follistatin to modulate growth and differentiation factor 8 [GDF-8] and bone morphogenic protein 11 [BMP-11] |
WO1999056768A1 (en) * | 1998-05-06 | 1999-11-11 | Metamorphix, Inc. | Methods for treating diabetes by inhibiting gdf-8 |
WO2000029570A1 (fr) * | 1998-11-13 | 2000-05-25 | Takeda Chemical Industries, Ltd. | Nouvelle proteine et son utilisation |
MXPA01007366A (es) * | 1999-01-21 | 2002-06-04 | Metamorphix Inc | Inhibidores de factores de crecimiento y diferenciacion y usos de los mismos. |
WO2001053350A1 (en) * | 2000-01-18 | 2001-07-26 | Agresearch Limited | Myostatin and mimetics thereof |
-
2000
- 2000-07-27 US US09/626,896 patent/US6656475B1/en not_active Expired - Lifetime
-
2001
- 2001-07-26 DK DK01961756.2T patent/DK1317485T3/da active
- 2001-07-26 EP EP10183121.2A patent/EP2322199B1/en not_active Expired - Lifetime
- 2001-07-26 MX MXPA03000787A patent/MXPA03000787A/es active IP Right Grant
- 2001-07-26 AU AU2001282999A patent/AU2001282999B2/en not_active Ceased
- 2001-07-26 ES ES01961756T patent/ES2364126T3/es not_active Expired - Lifetime
- 2001-07-26 DE DE60144334T patent/DE60144334D1/de not_active Expired - Lifetime
- 2001-07-26 AU AU8299901A patent/AU8299901A/xx active Pending
- 2001-07-26 AT AT01961756T patent/ATE503487T1/de active
- 2001-07-26 IL IL15397501A patent/IL153975A0/xx unknown
- 2001-07-26 PL PL01365792A patent/PL365792A1/xx not_active Application Discontinuation
- 2001-07-26 NZ NZ523617A patent/NZ523617A/en not_active IP Right Cessation
- 2001-07-26 CN CNA2008101449332A patent/CN101402955A/zh active Pending
- 2001-07-26 CA CA2417568A patent/CA2417568C/en not_active Expired - Fee Related
- 2001-07-26 PT PT01961756T patent/PT1317485E/pt unknown
- 2001-07-26 CN CNB018149081A patent/CN100422212C/zh not_active Expired - Lifetime
- 2001-07-26 ES ES10183121.2T patent/ES2532406T3/es not_active Expired - Lifetime
- 2001-07-26 BR BR0112788-8A patent/BR0112788A/pt not_active IP Right Cessation
- 2001-07-26 WO PCT/US2001/023615 patent/WO2002010214A2/en active Application Filing
- 2001-07-26 JP JP2002515943A patent/JP5153985B2/ja not_active Expired - Fee Related
- 2001-07-26 NZ NZ535074A patent/NZ535074A/en not_active IP Right Cessation
- 2001-07-26 EP EP01961756A patent/EP1317485B1/en not_active Expired - Lifetime
- 2001-07-27 AR ARP010103595A patent/AR033384A1/es unknown
-
2003
- 2003-01-17 ZA ZA200300480A patent/ZA200300480B/en unknown
-
2009
- 2009-05-18 IL IL198800A patent/IL198800A0/en unknown
-
2012
- 2012-06-29 JP JP2012147832A patent/JP5785525B2/ja not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
JP2012235781A (ja) | 2012-12-06 |
EP2322199B1 (en) | 2014-12-10 |
EP1317485B1 (en) | 2011-03-30 |
ATE503487T1 (de) | 2011-04-15 |
CA2417568A1 (en) | 2002-02-07 |
CN100422212C (zh) | 2008-10-01 |
ZA200300480B (en) | 2004-01-27 |
WO2002010214A3 (en) | 2003-04-03 |
CN101402955A (zh) | 2009-04-08 |
EP1317485A2 (en) | 2003-06-11 |
WO2002010214A2 (en) | 2002-02-07 |
JP5153985B2 (ja) | 2013-02-27 |
NZ535074A (en) | 2005-12-23 |
PT1317485E (pt) | 2011-07-06 |
CA2417568C (en) | 2014-07-08 |
IL198800A0 (en) | 2010-02-17 |
DK1317485T3 (da) | 2011-07-18 |
JP2004504832A (ja) | 2004-02-19 |
AU2001282999C1 (en) | 2002-02-13 |
ES2364126T3 (es) | 2011-08-25 |
JP5785525B2 (ja) | 2015-09-30 |
AU2001282999B2 (en) | 2006-12-14 |
AR033384A1 (es) | 2003-12-17 |
CN1449410A (zh) | 2003-10-15 |
NZ523617A (en) | 2005-05-27 |
AU8299901A (en) | 2002-02-13 |
DE60144334D1 (de) | 2011-05-12 |
ES2532406T3 (es) | 2015-03-26 |
IL153975A0 (en) | 2003-07-31 |
PL365792A1 (en) | 2005-01-10 |
EP2322199A1 (en) | 2011-05-18 |
US6656475B1 (en) | 2003-12-02 |
BR0112788A (pt) | 2003-09-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA03000787A (es) | Receptores del factor de diferenciacion de crecimiento, agonistas y antagonistas de los mismos, y metodos de usarlos. | |
WO2002085306A3 (en) | Use of follistatin to increase muscle mass | |
AU7197796A (en) | Calcium receptor active molecules | |
Erne-Brand et al. | Mechanism of antinociceptive action of clonidine in nonmyelinated nerve fibres | |
WO2003103697A3 (en) | USE OF COMPOUNDS HAVING GIP ACTIVITY IN THE TREATMENT OF DISORDERS ASSOCIATED WITH ABNORMAL CELL LOSS AND / OR IN THE TREATMENT OF OBESITY | |
BR9815340A (pt) | Utilização de pelo menos um ativador dos receptores de tipo ppar-y. | |
CA2246839A1 (en) | Pharmaceutical compositions containing ampa receptor antagonists for treating dyskineslas associated with dopamine agonist therapy | |
MX9604100A (es) | Compuestos ciclicos, inhibidores de la adhesion. | |
CA2339093A1 (en) | Cholinergic agents in the treatment of presbyopia | |
AUPO755097A0 (en) | Receptor agonist and antagonist | |
DE69926919D1 (de) | N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren | |
AP2001002129A0 (en) | 5HT1 receptor agonists and metoclopramide for the treatment of migrane. | |
AU5608000A (en) | 22025, a novel human cyclic nucleotide phosphodiesterase | |
TR199802596T2 (xx) | Desmopressinin burundan kullan�lmas� | |
Mirfendereski et al. | Pituitary adenylate cyclase activating peptide (PACAP) in salivary glands of the rat: origin, and secretory and vascular effects | |
YU70199A (sh) | Primena stimulatora lučenja hormona rasta za izradu farmaceutskih preparata za lečenje otpornosti na insulin | |
GB2352972A (en) | Use of dexmedetomidine for icu sedation | |
Scheja et al. | Serum levels of aminoterminal type III procollagen peptide and hyaluronan predict mortality in systemic sclerosis | |
EP0948536A4 (en) | PROTEIN G ASSOCIATED RECEPTOR HAVING ENLARGED EXTRACELLULAR DOMAIN | |
WO2001017558A3 (en) | Novel uses of mammalian ccr6 receptors and related reagents | |
ATE242641T1 (de) | Behandlung von stressinduzierten hautkrankheiten unter verwendung von corticoliberin (crh)- antagonisten und inhibitoren der hautmastzell- degranulation | |
AU7439996A (en) | Novel uses of mammalian ctla-8 and related reagents | |
AU2204701A (en) | Formulations of adenosine a1 agonists | |
Coughlan et al. | Application and modification of the fish health assessment index used for largemouth bass in the Catawba River, North Carolina-South Carolina | |
Suria et al. | Diazepam inhibition of post-tetanic potentiation in bullfrog sympathetic ganglia: possible role of prostaglandins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |